PARAGONE primarily focuses on taking previously identified promising prototype vaccines to the later stages of proof of concept and beyond, with the main objectives for these being:
- Improvement of previously demonstrated efficacy levels
- Making the production process more efficient and cost effective and/or
- Investigating multivalency potential of some the prototypes
This will ensure that the vaccines have practical and commercial value in the long term
Pathway to Impact Plan
Demonstration of significant or improved protection in vaccine trials held in WP1.
Activates discussions with WP3 & WP4 Leaders with aim of transitioning work to adjuvant testing (WP3) and/or field trials (WP4).
Completion of key activities in WP 1, 2, 3 & 4 activates discussions with commercial partners on whether to exercise commercial option to move to product development. Key activities being:
Pivot points to access information from end-users & stakeholders informs on acceptable vaccine formulation/design to ensure that the end products are fit-for- purpose.
Feedback from end-users and stakeholders obtained via dissemination & communication interactions which are discussed at 6-monthly WP4 meetings with the intent of designing products to achieve maximal uptake after preclinical/clinical development.
Key information will be transferred to these audiences during consortium communication activities to make them aware of the prospect of vaccines coming to market for parasite control.
Interactions between scientists, pharma & Scientific Advisory Panel experts
Seminars from academic & industrial partners
Interactions between scientists & stakeholders
PARAGONE will thus develop a product pipeline based on user-relevant platforms that will facilitate integration into disease control strategies on farms in different geographical locations.
